ProPhase Labs, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
ProPhase Labs, Inc. (PRPH) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $959.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-19
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $959.00K.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.60M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $646.00K.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.29M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $959.00K 10-Q · filed 2026-08-19 |
| 2026-03-31 | $1.60M 10-Q/A · filed 2026-07-09 |
| 2025-09-30 | $646.00K 10-Q · filed 2025-11-19 |
| 2025-06-30 | $1.29M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $1.94M 10-Q · filed 2025-05-20 |
| 2024-09-30 | $646.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $1.29M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $1.94M 10-Q · filed 2024-05-10 |
| 2023-09-30 | $682.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $1.44M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $2.19M 10-Q · filed 2023-05-12 |
| 2022-09-30 | $414.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $960.00K 10-Q · filed 2022-08-12 |
| 2021-09-30 | $709.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |